Matches in Wikidata for { <http://www.wikidata.org/entity/Q97675085> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q97675085 description "artículu científicu espublizáu en xunetu de 2020" @default.
- Q97675085 description "im Juli 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q97675085 description "scientific article published on 22 July 2020" @default.
- Q97675085 description "wetenschappelijk artikel" @default.
- Q97675085 description "наукова стаття, опублікована 22 липня 2020" @default.
- Q97675085 name "Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK" @default.
- Q97675085 name "Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK" @default.
- Q97675085 type Item @default.
- Q97675085 label "Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK" @default.
- Q97675085 label "Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK" @default.
- Q97675085 prefLabel "Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK" @default.
- Q97675085 prefLabel "Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK" @default.
- Q97675085 P1433 Q97675085-44B574F8-2510-4A49-9C2B-CD98736D1B12 @default.
- Q97675085 P1476 Q97675085-13B36895-F068-41EB-9B34-5B94D637C124 @default.
- Q97675085 P2093 Q97675085-715C7005-CB94-4C86-97E4-0A831DF0B848 @default.
- Q97675085 P2093 Q97675085-795E1662-C39F-4ACB-B888-B647B57694B6 @default.
- Q97675085 P2093 Q97675085-824BAC22-6F56-4C63-BACE-87CDE8D397BB @default.
- Q97675085 P2093 Q97675085-B256DF23-F28B-466F-9406-3B9C0C8C9103 @default.
- Q97675085 P2093 Q97675085-B36677A6-4E42-49E3-8AA2-FE1F4186477A @default.
- Q97675085 P2093 Q97675085-EB0D0CB9-90AE-451D-A60F-F72C60CDC0FE @default.
- Q97675085 P31 Q97675085-190A7EF8-7470-4534-9BFF-60EE25ADA0D8 @default.
- Q97675085 P356 Q97675085-CE65E500-C06C-4992-A754-98848F2D147D @default.
- Q97675085 P577 Q97675085-5543CA75-82C2-443B-B59F-E3F95A7A8620 @default.
- Q97675085 P698 Q97675085-FD1C1AC2-CDE3-46CE-B990-6172AC3C8B31 @default.
- Q97675085 P921 Q97675085-00DC47B6-48D4-4203-8ECC-BDD41FA16076 @default.
- Q97675085 P921 Q97675085-0B74BF91-E396-4F59-A06C-C291412720CB @default.
- Q97675085 P921 Q97675085-2451D0E1-EACF-456B-8BE6-056E03F80224 @default.
- Q97675085 P921 Q97675085-811FDC97-4AF9-48FD-9B88-E6A8554B0F47 @default.
- Q97675085 P356 S13300-020-00883-1 @default.
- Q97675085 P698 32700188 @default.
- Q97675085 P1433 Q26853803 @default.
- Q97675085 P1476 "Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK" @default.
- Q97675085 P2093 "Anastasia Ustyugova" @default.
- Q97675085 P2093 "Mafalda Ramos" @default.
- Q97675085 P2093 "Mark Lamotte" @default.
- Q97675085 P2093 "Michael H Cummings" @default.
- Q97675085 P2093 "Shamika U de Silva" @default.
- Q97675085 P2093 "Syed I Raza" @default.
- Q97675085 P31 Q13442814 @default.
- Q97675085 P356 "10.1007/S13300-020-00883-1" @default.
- Q97675085 P577 "2020-07-22T00:00:00Z" @default.
- Q97675085 P698 "32700188" @default.
- Q97675085 P921 Q19484 @default.
- Q97675085 P921 Q27261089 @default.
- Q97675085 P921 Q3025883 @default.
- Q97675085 P921 Q5373824 @default.